Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00717236 · ClinicalTrials.gov registry record · Phase 3
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase 3 study of Rheumatoid Arthritis, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,648
- Enrollment target
- 20
- Study locations
NCT00717236 is a Phase 3 study of Rheumatoid Arthritis that has completed, run by UCB Pharma. The registered enrollment target is 1,648 participants, below the 4,682-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT00717236, a Phase 3 study of Rheumatoid Arthritis, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,648 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase IIIb multicenter study to evaluate the safety and efficacy of certolizumab pegol (CZP) administered to patients with moderate-to-severe rheumatoid arthritis.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Certolizumab pegol (CZP)
Study Locations (20)
California
- - Fullerton
- - La Jolla
- - Los Angeles
- - Palm Desert
- - Sacramento
- - Santa Barbara
- - Santa Maria
- - Tustin
- - Westlake Village
- - Whittier
Alabama
- - Birmingham
- - Montgomery
Arizona
- - Phoenix
- - Tucson
Arkansas
- - Hot Springs
- - Little Rock
Connecticut
- - Danbury
- - Trumbull
Colorado
- - Denver
Delaware
- - Lewes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,648 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00717236
The ClinicalTrials.gov registry entry for NCT00717236 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,648 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,682-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (65% lower). The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00717236 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00717236 about?
NCT00717236 is a clinical study titled "Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis". This is a Phase IIIb multicenter study to evaluate the safety and efficacy of certolizumab pegol (CZP) administered to patients with moderate-to-severe rheumatoid arthritis.
What is the current status of trial NCT00717236?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,648 participants. The study started on 2008-07. Estimated completion is 2011-03.
What conditions does trial NCT00717236 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT00717236?
The interventions under investigation include: Placebo (OTHER), Certolizumab pegol (CZP) (DRUG).
Who is sponsoring clinical trial NCT00717236?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00717236 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
RECRUITING · Phase 3
-
Ra-pro Pragmatic Trial
RECRUITING · Phase 3
-
Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
-
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.